Contract Manufacturing, Biopharmaceutical Production

Collaboration will provide for unified development and manufacture of antibody drug conjugates.

Changes in China’s Food and Drug Administration (cFDA) drug development and commercialization policies make it easier for multinationals and CMOs to manufacture in China for in-country use, reports CMO and consultant PaizaBio.

Better process development is creating industry benchmarks for bioprocessing.

Althea is expanding its existing biological drug product manufacturing operations to include highly active materials, such as antibody-drug conjugates, in a new facility near San Diego, CA.

BioPharm International eBooks

Vetter plans to invest approximately 300 million Euros during the course of five years to expand drug product manufacturing and logistic services in Germany; upgrades will include an improved RABS system for aseptic processing.

Focusing on niche and specialty service offerings gives contract biomanufacturing organizations an opportunity to differentiate in a crowded market.

CMC Biologics and River Vision Development announce manufacturing agreement for RV001, a monoclonal antibody to treat Grave’s orbitopathy.

While the United States and Europe still dominate, CMOs and CROs based in emerging markets continue to capture market share.

Rentschler Biotechnologie launches 2000-L single-use bioreactor and announces additional expansion.

The fast growth of the global biopharmaceutical market has prompted global pharmaceutical and biotechnology companies to increase their R&D investment in biologics.

There are significant differences between small molecules and biologics fill/finish capacity.

A dynamic market, industry consolidation, and demand fluctuations lead to a mixed picture of pricing results.

Representatives of contract service organizations discuss technology trends with BioPharm International.

The author highlights the top 10 outsourcing trends found during a survey of biopharmaceutical manufacturers.

Advances in techniques and single-use systems are revolutionizing vaccine manufacturing.

Successful management of the CMO/client relationship should include open communication and trust.

Will international biomanufacturing outsourcing become mainstream in this decade?

The manufacturing capacity-sharing model between Merck and MedImmune ushers in a new paradigm of "co-opetition."

Measuring the size of the market for contract manufacturing services requires a careful hand.

Marco Chacon of Paragon Bioservices discusses the challenges associated with outsourced vaccine manufacturing.

Industry wants more innovation, but can suppliers meet customers' needs?

Industry experts discuss significant achievements. Plus: What's in store for the future.

Because of the complexity of the manufacturing processes for biologics, transfer of these processes to a contract manufacturer presents challenges.

Industry optimism is on the rise for 2012.